Research spotlight: Tools for eradicating HIV in the brain: Prodrug dimeric inhibitors of P-gp

Therapeutic Delivery

Volumn 3, Issue 6, 2012, Pages 689-692

  Chmielewski, Jean ^a   Hrycyna, Christine ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIINFECTIVE AGENT; BREAST CANCER RESISTANCE PROTEIN; EMETINE; GLYCOPROTEIN P; INDINAVIR; MONOMER; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 3; NELFINAVIR; PRODRUG; QUININE; RITONAVIR; SAQUINAVIR; STIPIAMIDE; UNCLASSIFIED DRUG; ZOSUQUIDAR; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG CARRIER; MULTIDRUG RESISTANCE PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; BLOOD BRAIN BARRIER; BRAIN INFECTION; CYTOSOL; DIMERIZATION; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; ENDOTHELIUM CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INHIBITION KINETICS; IONIZATION; LIPOPHILICITY; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TIGHT JUNCTION; VIRUS CARRIER; VIRUS EXPRESSION; ANIMAL; BRAIN; CAPILLARY PERMEABILITY; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; DRUG FORMULATION; METABOLISM; METHODOLOGY; OXIDATION REDUCTION REACTION; PHARMACEUTICS; T LYMPHOCYTE; TRANSPORT AT THE CELLULAR LEVEL; VIROLOGY;

ANIMALS; ANTI-HIV AGENTS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; CAPILLARY PERMEABILITY; CHEMISTRY, PHARMACEUTICAL; DIDEOXYNUCLEOSIDES; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DESIGN; HIV INFECTIONS; HUMANS; OXIDATION-REDUCTION; P-GLYCOPROTEIN; PRODRUGS; T-LYMPHOCYTES; TECHNOLOGY, PHARMACEUTICAL;

EID: 84861826206     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.49     Document Type: Article

References (20)

1. Lambotte O, Deiva K, Tardieu M. HIV-1 persistence, viral reservoir, and the central nervous system in the HAART era. Brain Pathol. 13, 95-103 (2003).
2. Saksena N, Wang B, Zhou L, Soedjono M, Ho YS, Conceicao V. HIV reservoirs in vivo and new strategies for possible eradication of HIV from the reservoir sites. HIV AIDS Res. Palliat. Care 2, 103-122 (2010).
3. Kandanearatchi A, Williams B, Everall IP. Assessing the efficacy of highly active antiretroviral therapy in the brain. Brain Pathol. 13, 104-110 (2003).
4. Letendre S, Marquie-Beck J, Capparelli E et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch. Neurol. 65, 65-70 (2008).
5. Tozzi V, Balestra P, Salvatori MF et al. Changes in cognition during antiretroviral therapy: Comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-Associated neurocognitive disorders. J. Acquir. Immune Defic. Syndr. 52, 56-63 (2009).
6. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science 323, 1304-1307 (2009).
7. Trono D, Van Lint C, Rouzioux C et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 329, 174-180 (2010).
8. Thomas SA. Anti-HIV drug distribution to the central nervous system. Curr. Pharm. Des. 10, 1313-1324 (2004).
9. Gimenez F, Fernandez C, Mabondzo A. Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins. J. Acquir. Immune Defic. Syndr. 36, 649-658 (2004).
10. Varatharajan L, Thomas SA. The transport of anti-HIV drugs across blood-CNS interfaces: Summary of current knowledge and recommendations for further research. Antiviral Res. 82, A99-A109 (2009).
11. Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci. 6, 591-602 (2005).
12. Gottesman MM, Hrycyna CA, Schoenlein PV, Germann UA, Pastan I. Genetic analysis of the multidrug transporter. Annu. Rev. Genet. 29, 607-649 (1995).
13. Raviv Y, Pollard HB, Bruggemann EP, Pastan I, Gottesman MM. Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J. Biol. Chem. 265, 3975-3980 (1990).
14. Aller SG, Yu J, Ward A et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323, 1718-1722 (2009).
15. Cameron DW, Japour AJ, Xu Y et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 13, 213-224 (1999).
16. Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: Implications for drug interactions. Ann. Pharmacother. 42, 1048-1059 (2008).
17. Sauna ZE, Andrus MB, Turner TM, Ambudkar SV. Biochemical basis of polyvalency as a strategy for enhancing the efficacy of P-glycoprotein (ABCB1) modulators: Stipiamide homodimers separated with defined-length spacers reverse drug efflux with greater efficacy. Biochemistry 43, 2262-2271 (2004).
18. Pires MM, Hrycyna CA, Chmielewski J. Bivalent probes of the human multidrug transporter P-glycoprotein. Biochemistry 45, 11695-11702 (2006).
19. Pires MM, Emmert D, Hrycyna CA, Chmielewsk J. Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers. Mol. Pharmacol. 75, 92-100 (2009).
20. Namanja HA, Emmert D, Davis DA et al. Toward eradicating HIV reservoirs in the brain: Inhibiting P-glycoprotein at the blood-brain barrier with prodrug abacavir dimers. J. Am. Chem. Soc. 134, 2976-2980 (2012).